The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2016
Filed:
Dec. 20, 2012
Abbott Molecular Inc., Des Plaines, IL (US);
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
Irina Sokolova, Villa Park, IL (US);
Larry Morrison, Oro Valley, AZ (US);
Ekaterina Pestova, Glenview, IL (US);
Emily Barr Fritcher, Rochester, MN (US);
Lewis Roberts, Rochester, MN (US);
Gregory Gores, Rochester, MN (US);
Kevin Halling, Rochester, MN (US);
Benjamin Kipp, Rochester, MN (US);
Abbott Molecular Inc., Des Plaines, IL (US);
Mayo Foundation For Medical Education and Research, Rochester, MN (US);
Abstract
A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient.